文献速递癫痫

脑反应性神经刺激治疗局灶性癫痫的九年前瞻性疗效与安全性

Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy.
PubMed 文献 · Neurology · 2020-07-20

本研究对256例药物难治性局灶性发作癫痫成人患者进行长期前瞻性开放标签试验,评估脑反应性神经刺激的安全性和疗效。9年时癫痫发作频率中位降低75%,应答率73%,18.4%患者曾至少1年无发作,生活质量持续改善,且未发现刺激相关严重不良事件,SUDEP率低于预设对照。

要点

  • 9年时癫痫发作频率中位降低75%,应答率73%,35%患者发作减少≥90%。
  • 18.4%患者曾至少1年无发作,其中62%末次随访仍无发作,平均无发作期3.2年。
  • 生活质量持续改善,无刺激相关严重不良事件,SUDEP率显著低于预设对照。

核心结论

  • 辅助性脑反应性神经刺激可显著且持续减少局灶性发作频率,并改善生活质量。
  • 刺激耐受性良好,植入相关不良事件与其他神经刺激装置类似,SUDEP率低。

研究设计与样本

  • 长期前瞻性开放标签试验,纳入初始2年可行性或随机对照试验中接受脑反应性神经刺激的成人药物难治性局灶性发作癫痫患者。
  • 共256例患者接受初始治疗,其中230例参与长期试验,额外评估7年,总随访9年。

主要发现

  • 9年时癫痫发作频率中位降低75%(p < 0.0001,Wilcoxon符号秩检验),应答率73%,35%患者发作减少≥90%。
  • 18.4%(47/256)患者曾至少1年无发作,其中62%(29/47)末次随访仍无发作,平均无发作期3.2年(范围1.04-9.6年)。
  • QOLIE-89总体生活质量、癫痫相关和认知域评分持续显著改善(p < 0.05)。
  • 无刺激相关严重不良事件,SUDEP率显著低于预设对照(p < 0.05,单侧χ2检验)。

关键数值与推荐

  • 9年时发作频率中位降低75%,应答率73%,≥90%发作减少者占35%。
  • 至少1年无发作率18.4%(47/256),末次随访无发作率62%(29/47),平均无发作期3.2年(范围1.04-9.6年)。

临床怎么用

  • 对于药物难治性局灶性发作癫痫成人患者,脑反应性神经刺激可作为辅助治疗选择,长期应用可持续减少发作并改善生活质量。
  • 植入相关不良事件与其他神经刺激装置类似,需关注但未发现刺激相关严重不良事件。

局限性

  • 本研究为开放标签试验,证据等级为Class IV。
  • 长期试验仅纳入初始试验中的部分患者(230/256),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To prospectively evaluate safety and efficacy of brain-responsive neurostimulation in adults with medically intractable focal onset seizures (FOS) over 9 years. METHODS: Adults treated with brain-responsive neurostimulation in 2-year feasibility or randomized controlled trials were enrolled in a long-term prospective open label trial (LTT) to assess safety, efficacy, and quality of life (QOL) over an additional 7 years. Safety was assessed as adverse events (AEs), efficacy as median percent change in seizure frequency and responder rate, and QOL with the Quality of Life in Epilepsy (QOLIE-89) inventory. RESULTS: Of 256 patients treated in the initial trials, 230 participated in the LTT. At 9 years, the median percent reduction in seizure frequency was 75% (p < 0.0001, Wilcoxon signed rank), responder rate was 73%, and 35% had a ≥90% reduction in seizure frequency. We found that 18.4% (47 of 256) experienced ≥1 year of seizure freedom, with 62% (29 of 47) seizure-free at the last follow-up and an average seizure-free period of 3.2 years (range 1.04-9.6 years). Overall QOL and epilepsy-targeted and cognitive domains of QOLIE-89 remained significantly improved (p < 0.05). There were no serious AEs related to stimulation, and the sudden unexplained death in epilepsy (SUDEP) rate was significantly lower than predefined comparators (p < 0.05, 1-tailed χ2). CONCLUSIONS: Adjunctive brain-responsive neurostimulation provides significant and sustained reductions in the frequency of FOS with improved QOL. Stimulation was well tolerated; implantation-related AEs were typical of other neurostimulation devices; and SUDEP rates were low. CLINICALTRIALSGOV IDENTIFIER: NCT00572195. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that brain-responsive neurostimulation significantly reduces focal seizures with acceptable safety over 9 years.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology. 2020. PMID: 32690786. doi:10.1212/WNL.0000000000010154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。